Effects on the Immune System 417Devane WA, Dysarz FA, III, Johnson MR, Melvin LS, Howlett AC (1988) Determination and
characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605–613
DevaneWA,HanusL,BreuerA,PertweeRG,StevensonLA,GriffinG,GibsonD,Mandelbaum
A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that
binds to the cannabinoid receptor. Science 258:1946–1949
Di Franco MJ, Sheppard HW, Hunter DJ, Tosteson TD, Ascher MS (1996) The lack of
association of marijuana and other recreational drugs with progression to AIDS in the
San Francisco Men’s Health Study. Ann Epidemiol 6:283–289
Diaz S, Specter S, Coffey RG (1993) Suppression of lymphocyte adenosine 3’:5’-cyclic
monophosphate (cAMP) by delta-9-tetrahydrocannabinol. Int J Immunopharmacol
15:523–532
DiazS,SpecterS,VanderhoekJY,CoffeyRG(1994)Theeffectofdelta-9-tetrahydrocannabinol
on arachidonic acid metabolism in human peripheral blood mononuclear cells. J Phar-
macol Exp Ther 268:1289–1296
Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A (1995) Mast cells ex-
press a peripheral cannabinoid receptor with differential sensitivity to anandamide and
palmitoylethanolamide. Proc Natl Acad Sci U S A 92:3376–3380
Felder CC, Veluz JS, Williams HL, Briley EM, Matsuda LA (1992) Cannabinoid agonists
stimulate both receptor- and non-receptor-mediated signal transduction pathways in
cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol
42:838–845
Fischer-Stenger K, Updegrove AW, Cabral GA (1992) Delta-9-tetrahydrocannabinol de-
creases cytotoxic T lymphocyte activity to herpes simplex virus type 1-infected cells.
Proc Soc Exp Biol Med 200:422–430
Fischer-Stenger K, Dove Pettit DA, Cabral GA (1993) Delta-9-tetrahydrocannabinol inhibi-
tion of tumor necrosis factor-alpha: suppression of post-translational events. J Pharma-
col Exp Ther 267:1558–1565
Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, Barda L, Blau H, Mechoulam R
(2003) Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice:
evidence for a “CB3” receptor. Eur J Pharmacol 461:27–34
Friedman H, Klein T, Specter S (1991) Immunosuppression by marijuana components. In:
Ader R, Felten DL, Cohen N (eds) Psychoneuroimmunology. Academic Press, San Diego,
pp 931–953
Friedman H, Newton C, Klein TW (2003) Microbial infections, immunomodulation, and
drugs of abuse. Clin Microbiol Rev 16:209–219
Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D,
Le Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors
in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54–61
Gallily R, Yamin A, Waksmann Y, Ovadia H, Weidenfeld J, Bar-Joseph A, Biegon A, Me-
choulam R, Shohami E (1997) Protection against septic shock and suppression of tumor
necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsy-
chotropic cannabinoid. J Pharmacol Exp Ther 283:918–924
Garry RF, Bishop JM, Parker S, Westbrook K, Lewis G, Waite MR (1979) Na+ and K+
concentrations and the regulation of protein synthesis in Sindbis virus-infected chick
cells. Virology 96:108–120
Garry RF, Ulug ET, Bose HR Jr (1982) Membrane-mediated alterations of intracellular Na+
and K+ in lytic-virus-infected and retrovirus-transformed cells. Biosci Rep 2:617–623
Goldsmith MA, Greene WC (1996) Interleukin-2 and interleukin-2 receptor. In: Thomas A
(ed) The cytokine handbook. Academic Press, New York, pp 57–80
Griffin G, Tao Q, Abood ME (2000) Cloning and pharmacological characterization of the
rat CB2 cannabinoid receptor. J Pharmacol Exp Ther 292:886–894
Gross A, Terraza A, Marchant J, Bouaboula M, Ouahrani-Bettache S, Liautard JP, Casellas
P, Dornand J (2000) A beneficial aspect of a CB1 cannabinoid receptor antagonist:
SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen
Brucella suis. J Leukoc Biol 67:335–344